These agents inhibit negative regulatory components of the immune response, such as the cytotoxic T lymphocytes-associated antigen 4 (CTLA-4) and the programmed cell death protein-1 and its ligand (PD-1/PD-L1), which lead to enhanced T cell action against the cancer cells (Hodi et al., 2010). The gene discussed is CD274; the disease is cancer.